A R T I C L E I N F O
3D mesoscopic fluorescence tomography for imaging micro-distribution of antibody-photon absorber conjugates during near infrared photoimmunotherapy in vivo As a novel low-side-effect cancer therapy, photo-immunotherapy (PIT) is based on conjugating monoclonal antibody (mAb) with a near-infrared (NIR) phthalocyanine dye IRDye700DX (IR 700). IR700 is not only fluorescent to be used as an imaging agent, but also phototoxic. When illuminating with NIR light, PIT can induce highly-selective cancer cell death while leaving most of tumor blood vessels unharmed, leading to an effect termed super-enhanced permeability and retention (SUPR), which can significantly improve the effectiveness of anti-cancer drug. Currently, the therapeutic effects of PIT are monitored using 2D macroscopic fluorescence reflectance imager, which lacks the resolution and depth information to reveal the 3D distribution of mAb-IR700. In the study, we applied a multi-modal optical imaging approach including high-resolution optical coherence tomography (OCT) and high-sensitivity fluorescence laminar optical tomography (FLOT), to provide 3D tumor micro-structure and micro-distribution of mAb-IR700 in the tumor simultaneously during PIT in situ and in vivo. The multi-wavelength FLOT can also provide the blood vessels morphology of the tumor. Thus, the 3D FLOT reconstructed images allow us to evaluate the IR700 fluorescence distribution change with respect to the blood vessels and at different tumor locations/depths non-invasively, thereby enabling evaluation of the therapeutic effects in vivo and optimization of treatment regimens accordingly. The mAb-IR700 can access more tumor areas after PIT treatment, which can be explained by increased vascular permeability immediately after NIR-PIT. Two-photon microscopy was also used to record the mAb-IR700 on the tumor surface near the blood vessels to verify the results.
Introduction
Enhancing drug delivery to cancers can significantly improve the effectiveness of therapy [1] . Targeted cancer therapies offer the promise of more effective tumor treatment with fewer side-effects than conventional cancer therapies. Molecular therapies based on monoclonal antibody (mAb) are highly-selective for tumors expressing particular antigens. However, patient outcomes have been only modestly improved when naked mAb is used as monotherapy or in combination with other therapies [2] [3] [4] . Combinations of conventional photosensitizers and mAbs have been tested but the improvement in selectivity is still limited [5] [6] [7] [8] . Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed specific cancer treatment that employs a targeted monoclonal antibody (mAb)-photo-absorber conjugate (mAC) [9] . The antibody binds to the appropriate target antigen of the cell surface and the photo-activatable silica-phthalocyanine dye, IRDye700DX (IR700), induces lethal damage to cell membrane after NIRlight exposure. NIR-PIT has been shown to be effective for various types of tumors with a variety of different antibodies [10] [11] [12] [13] [14] [15] [16] . Moreover, a first-in-human phase 1 trial of epidermal growth factor receptor (EGFR) targeted NIR-PIT in patients with inoperable head and neck cancer was initiated in June 2015 and has recently advanced to phase 2 [17] .
NIR-PIT induces selectively immediate target specific immunogenic cell death (ICD) and the non-target cells which locate next to the target cells are not damaged by therapy [9, 18] . Immediate cell death leads to immediate increases in vascular permeability of treated tumors which can result in 10-to 24-fold enhancement of macromolecules or nanodrugs delivery [19] . This phenomenon has been termed super enhanced permeability and retention (SUPR) effects because it is substantially greater than conventional "enhanced permeability and retention (EPR)" which is commonly seen in untreated tumors [1, [19] [20] [21] . We have investigated the mechanism for increased permeability of NIR-PIT into tumor tissue following treatment [19] [20] [21] . SUPR effects result in redistribution of already circulating mACs, at least partly overcoming baseline heterogeneity in drug delivery commonly observed in untreated tumors [1, 22] . Therefore, additional exposures of NIR-light can further improve therapeutic effects by depositing additional mACs in the tumor bed after initial NIR-PIT [23] . Real-time monitoring of theranostic agent distribution and therapeutic effects within the tumor micro-environment non-invasively will be critical for further understanding of PIT/SUPR mechanism and optimizing the effectiveness of treatment [22] .
Current approach for monitoring mACs fluorescence are based on macroscopic fluorescence reflectance imaging which lacks the resolution and depth information to reveal mAb-IR700 distribution in situ [19, 22] . Histological analysis can reveal intra-tumor inhomogeneity, but in an invasive and terminal manner [22] . We has investigated the micro-distribution of mACs at different locations during/after PIT in situ and in vivo using a two-channel fluorescence fiber imaging system and a high-resolution two-photon microscope interfaced with micro-prism previously [22] . However, both approaches are still invasive. Fluorescence laminar optical tomography (FLOT) [24] [25] [26] [27] [28] [29] [30] [31] [32] , or mesoscopic fluorescence molecular tomography (MFMT) [33] [34] [35] [36] [37] , is a promising three-dimensional (3-D) imaging approach that has a resolution of 100 μm with 2-3 mm penetration depth, which has the potential to quantify depth-resolved distribution of mACs in tumor. Optical coherence tomography (OCT) is an established biomedical imaging method for subsurface imaging of tissues microstructure with high resolution (< 10 μm) and 1-2 mm penetration depth [26, [38] [39] [40] [41] [42] [43] . Herein, we applied a multi-modal optical imaging approach including OCT and FLOT, to provide three-dimensional (3-D) tumor micro-structure and micro-distribution of mACs in the tumor simultaneously during cancer treatment in situ and in vivo. Multi-wavelength FLOT could also provide the blood vessels morphology on the tumor. Thus, 3D FLOT/OCT reconstructed images allow us to evaluate the real-time drug distribution change with respect to the blood vessels and at different tumor locations/depths in living mice. The high resolution two-photon microscopy was also used to record the mAb-IR700 on the tumor surface near the blood vessels to verify the results.
Materials and methods

Reagents
Water soluble, silica-phthalocyanine derivative, IRDye 700DX NHS ester was obtained from LI-COR Biosciences (Lincoln, NE, USA). Panitumumab, a fully humanized IgG2 monoclonal antibody (mAb) directed against EGFR, was purchased from Amgen (Thousand Oaks, GA, USA). All other chemicals were of reagent grade [22] .
Synthesis of IR700-conjugates
Conjugation of dyes with mAb was performed according to previous methods [9, 22] . In brief, panitumumab (1.0 mg, 6.8 nmol) was incubated with IR700 NHS ester (66.8 μg, 34.2 nmol) in 0.1 M Na2HPO4 (pH 8.6) at room temperature for 1 h. The mixture was purified with a Sephadex G25 column (PD-10; GE Healthcare, Piscataway, NJ, USA). The protein concentration was determined with Coomassie Plus protein assay kit (Thermo Fisher Scientific Inc., Rockford, IL, USA) by measuring the absorption at 595 nm with UV-VIS (8453 Value System; Agilent Technologies, Santa Clara, CA, USA). The concentration of IR700 was quantified by measuring the absorption at 689 nm to confirm the number of fluorophore molecules per mAb. The synthesis was controlled so that an average of two IR700 molecules was bound to a single antibody. We abbreviate IR700 conjugated to panitumumab as pan-IR700 [22] .
Cell culture
EGFR-expressing A431 cells (epidermoid carcinoma cells) and A431 cells stably expressing green fluorescent protein (GFP) cells were established by Dr. Kobayashi's laboratory. Cells were grown in RPMI 1640 medium (Life Technologies, Gaithersburg, MD USA) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Life Technologies) in tissue culture flasks in a humidified incubator at 37°C at an atmosphere of 95% air and 5% carbon dioxide [1, 22] .
Animal and tumor models
All in vivo procedures were conducted in compliance with the Guide for the Care and Use of Laboratory Animal Resources (1996), US National Research Council, approved by the Institutional Animal Care and Use Committees (IACUCs) at the University of Maryland and NIH. Six-to eight-week old female homozygous athymic nude mice were purchased from Charles River (NCI-Frederick, Frederick, MD, USA). Two-million A431/A431-GFP cells were subcutaneously injected in the right and left dorsum of each mouse. Tumor volume was based on caliper measurements and calculated using the following formula: tumor volume = length × width 2 × 0.5. Mice were monitored daily for their general health. Tumors reaching approximately 100 mm 3 in volume were selected for study [1, 22] .
Treatment regimens
We used pan-IR700 as the agent for A431/A431-GFP tumor bearing mice. Tumor bearing mice were randomized into 4 groups of at least 5 animals per group for each imaging experiment. A431 tumor bearing mice were used for PIT FLOT/OCT imaging experiment (group 1) and control FLOT/OCT imaging experiment (group 2). A431-GFP tumor bearing mice were used for PIT two-photon imaging (group 3) and control two-photon imaging experiment (group 4). 24 h after i.v. injection of 100 μg of pan-IR700 via the tail vein, 50 J/cm 2 NIR light was administered at group 1 and 3 while group 2 and 4 (without NIR light) were used as control.
Imaging
During the procedure, all mice were anesthetized with inhaling 2% isoflurane mixed in O 2 and were then immobilized using a customized stereotaxic frame with body temperature maintained at 37°C by a heating blanket. A small incision was performed to remove the skin covering the tumor for imaging. In FLOT/OCT experiments, 50 μL oregon green labeled dextran with 70,000 MW (Dextran, Oregon Green™ 514, Thermo Fisher Scientific Inc., Rockford, IL, USA) was injected i.v. (25 mg/mL) before NIR light administration to indicate the vascular distribution of the tumors. The mice were euthanized and tumors were extracted after imaging.
OCT system
Supplementary Fig. 1A illustrated the schematic of the OCT imaging system. This OCT imaging system was equipped with a wavelengthswept laser as light source which was centered at 1310 nm with 100 nm bandwidth as previously described [26, [44] [45] [46] [47] . The wavelength-swept frequency of the laser was 16 kHz with 17 mW output power [26, 46] . A fiber-based Michelson interferometer was used in the OCT system. About 97% of the laser power was split evenly to the sample and reference arms [26, 45] . The remaining 3% of the laser output power was obtained by a Mach-Zehnder interferometer (MZI) to generate a frequency-clock signal with uniformly spaced optical frequency to trigger the sampling of the OCT signal [27] . The reflected/backscattered signals from both the sample and reference arms encountered at the fiber couple (FC) and formed interference fringes [26] . The interference signals were then received by a balanced detector (BD). Depth-resolved tomography can finally be realized by performing fast Fourier transform of the interference fringes [26] as light reflected from different sample depths resulted in interference fringes with different frequencies.
FLOT system
The schematic of the FLOT system shown in Supplementary Fig . 1B was similar to that reported previously [29, 48, 49] . In brief, two pigtailed laser diodes centered at 658-nm and 520-nm (LP660-SF60 and LP520-SF15, Thorlabs Inc., Newton NJ, USA) were used as the light sources to illuminate the mice tumor at two wavelengths in a timeshared manner. The line-field illumination was achieved by a cylindrical lens shaping the collimated light. The line illumination had a full line-width at the half maximum of~26 μm at the focal plane [29, 49] . The backscattered light and emitted fluorescent light from the mice tumor passed through an objective lens, a filter wheel (695-nm and 561-nm long-pass emission filters for fluorescence imaging and no filter applied for reflectance images), and finally collected by a 12-bit CCD camera (EM-CCD, PCO-TECH Inc., Romulus MI, USA) [29, 49] . The mice tumor was scanned by translating the mice laterally in the scanning direction X (perpendicular to the line illumination direction Y) using a motorized stage (ESP301, Newport Corp, Irvine CA, USA). The acquired 3D OCT and FLOT datasets were co-registered as previously described [26] . In this study, IR700 was employed as fluorescence biomarkers for FLOT and as a surrogate of mACs accumulation.
Two-photon microscope (TPM) system
In this study, we employed a lab-customized two-photon system previously reported [22] . Briefly, the TPM system utilized a Ti:sapphire laser (Coherent Mira 900-F) operating at 790 nm wavelength with 120 fs pulse width. A 20× water immersion objective (Olympus Corporation) was applied. A customized dichroic mirror (760 nm, single edge dichroic beam splitter; T760LPXXR-UF3; Chroma Technology Corporation) was used to separate the excitation laser and fluorescence signals [22] . The emitted fluorescence signals were further separated into two channels by another 550 nm dichroic beam splitter. Emission filters (525 ± 39 nm and 716 ± 42 nm for the GFP signal in the green channel and the IR700 signal in the red channel, respectively) were employed before the photomultiplier tubes (H7422P-40 for green channel and H7422P-50 for red channel, Hamamatsu Corporation). In the experiments, the skin covering the tumor was removed and the tumor was exposed under the 20× objective lens. TPM can provide higher resolution but limited field of view. Herein, TPM was applied to support our FLOT results. In the TPM experiments, we employed GFP fluorescence as a surrogate of treatment and IR700 fluorescence as a surrogate of mACs accumulation as previously reported [1, 22] .
Data recording protocol
The NIR LED used for the PIT treatment in the experiments has a spectrum of 680-700 nm (Tech-LED, Marubeni America Co.) [22] . In order to deliver the dose of~50 J/cm 2 light on the tumor, the NIR LED need to irradiate for~20 min [50, 51] . Since the LED spectrum has overlap with the emission filter spectral range in both FLOT and TPM systems, to record the IR700 fluorescence signal change during and after PIT, the data acquisition protocol is designed as following: one dataset was acquired before turning on the NIR LED, then each dataset was taken after every 5-minute' NIR exposure on tumor. The NIR LED was turned off during data acquisition (~30 s). After a total of 20 min' NIR irradiation, the PIT treatment was finished and one dataset was taken every 5 min in the next 60 min to record the post-treatment redistribution of the mACs in the tumor. For the control group, one dataset was acquired every 5 min for 80 min without NIR LED exposure. In FLOT/OCT experiments, before the acquisition protocol described above, the tumor was first imaged by OCT system to provide the morphology of the tumor. In this study, the area within 500 μm depth from tumor surface was defined as tumor surface (tumor_s) and the area beyond 500 μm depth from tumor surface was defined as deep tumor (tumor_d) [22] .
Ex-vivo evaluation
To detect the antigen-specific micro-distribution in the tumor, fluorescence microscopy was performed. Extracted tumors were frozen with OCT compound (SAKURA Finetek Japan Co., Tokyo, Japan) and frozen sections (10 μm thick) were prepared. Fluorescence microscopy was performed using the BX61 microscope with the following filters; excitation wavelength 590 to 650 nm, emission wavelength 665 to 740 nm for IR700 fluorescence. Transmitted light differential interference contrast (DIC) images were also acquired. Extracted tumors were also placed in 10% formalin and serial 10 μm slice sections were fixed on glass slide with Hematoxylin and Eosin (H&E) staining. Light microscopy study was also performed using Olympus BX61 to evaluate histological changes.
Statistical analysis
There are no missing data observed in this study. Descriptive statistics (e.g. mean and standard deviation) were calculated. Student t-test was used and statistical analyses were performed using MATLAB (The MathWorks Inc., Natick, MA) with statistical significance p = 0.05.
Results and discussion
Calibration of the FLOT system
In our previous paper, quantum-dot-embedded EH-PEG hydrogel was used to characterize the PSF (point spread function) of our FLOT system [29] . To further characterize the FLOT system, liquid phantoms were fabricated. IRDye 700DX NHS ester (IR700), intralipid solution (Hospira Inc.), and PBS buffer were mixed and stirred well. The intralipid concentration was set to provide a reduced scattering coefficient μ s ′ =~0.5/mm at 635 nm, which is very similar to optical properties of the tumors used in this experiment determined from the reflectance data using oblique-incidence spectroscopy [52] [53] [54] . Different IR700 concentrations between 0 and 5 μM were diluted to test the fluorescence signals at different depths of our FLOT system and the depth profiles do not change much for different IR700 concentrations as shown in Supplementary Fig. 1C . Since the liquid phantoms are homogeneous, the fluorescence signals are supposed to be the same at different depths, while we can notice that there are some decreases in fluorescence as depth increases due to the imperfect reconstruction nature of our FLOT system. We further plotted the normalized fluorescence intensity of homogenous phantoms and tumors at different depths as shown in Supplementary Fig. 1D . To improve the accuracy of our results, we extracted a weight matrix from the normalized fluorescence intensity of homogenous phantoms at different depths to compensate for the depth-dependent signal decrease from the FLOT system. All the datasets in the following studies were compensated by the weight matrix before further processing to eliminate the signal decrease. Normalized fluorescence intensity of tumors after compensation at different depths was also shown in Supplementary Fig. 1D . Different IR700 concentrations from 0 to 10 μM were diluted to test the sensitivity of our FLOT system in Supplementary Fig. 1E , showing an excellent linear response with R 2 = 0.9918. To make our FLOT results more quantitative and select a proper threshold, we imaged 6 blank tumors without any drug injected. The limit of quantification (LOQ) is defined as: LOQ = M + 10σ, where M is the average intensity of the blank tumors after compensation (background) and σ is the standard deviation of the blank tumors [55] . Supplementary Fig. 1F shows the fluorescence intensity change at different depths in the mice tumors after compensation. From this definition we can estimate the imaging depth of our FLOT system is~2 mm in the mouse tumor with current setup. Then we applied the LOQ values as a global threshold for the following quantitative analysis. All the pixels in the 3D FLOT data over the global threshold (LOQ) are defined as the ROIs.
3.2. In vivo 3D imaging the distribution of the mACs using FLOT/OCT system Fig. 1A shows the 3D tumor structure obtained from OCT, with the tumor outlined by the blue dashed margin. High-resolution OCT can reveal the microstructure surrounding the tumor (e.g. the fiber tissue covering the tumor can be clearly seen). Fig. 1B is the cross-sectional OCT image from the green dashed line in Fig. 1A . The tumor area is easy to be distinguished from the surrounding tissues. The muscle tissue on the left of the tumor tissue featured with bright and dark horizontal stripes due to birefringence. The tumor tissue has less penetration depth compared with normal tissue due to increased tissue scattering [26] . Fig. 1C shows the fused OCT/FLOT image with red-orange colour indicating the distribution of mACs. Fig. 1D shows fused cross-sectional OCT/FLOT image with depth-resolved distribution of the mACs scattered inside the tumor. We first evaluated the fluorescence intensity from tumor surface (indicated in blue dashed box in Fig. 1D ) and deep tumor (indicated in red dashed box in Fig. 1D ) in the anesthetized mice before PIT treatment. From the results of FLOT, IR700 fluorescence intensity in the tumor surface was significantly higher than that of the deep tumor (Fig. 1E) , which is consistent with our previous results [22] . Moreover, we plotted the normalized fluorescence intensity of homogenous phantoms and tumors at different depths before compensation as shown in Supplementary Fig. 1D . The quicker drop of fluorescence intensity in tumors compared to the homogenous phantoms also implied more mACs in tumor surface. Ex-vivo DIC images confirmed relatively homogeneous cell distribution across the tumor surface and deep tumor, while IR700 fluorescence intensity in tumor surface was also significantly higher than that of the deep tumor (Supplementary Fig. 2A-C) .
The mAb-IR700 distribution during and after PIT treatment was shown in Fig. 1F . At 0 min, NIR LED irradiation began and the IR700 fluorescence intensity dropped quickly at both tumor surface and deep tumor regions in the first 20 min. After 20 min, the NIR LED was turned off and the PIT treatment finished. The IR700 fluorescence intensity began to recover and interestingly the fluorescence distribution achieved a bigger volume than the initial value (0 min), meaning the drug accessed more tumor areas after NIR-PIT treatment.
To quantify the 3D images acquired by FLOT, the IR700 fluorescence intensity was averaged and normalized to the initial level (0 min). The normalized IR700 fluorescence intensity showed a clearly drop in the first 20 min during PIT treatment and a recovery in the following 60 min, while there was only gradual decrease in controls without any fluorescence recovery which may result from dye photo-bleaching ( Fig. 2A) . To investigate the 3D micro-distribution of mACs, we plotted out the histogram of the pixels in the tumor. One pixel can represent a voxel in the tumor and the pixel intensity can reflect the density of the mACs in this voxel. The histograms of the pixel intensity before and 60 min after PIT in the tumor were shown in Fig. 2B . 60 min after PIT treatment, the whole histogram shifted to the middle range while the control group did not have such trend (Fig. 2C) . Before PIT treatment, due to the heterogeneous vascularity, increased interstitial pressure and structural barriers imposed by the extracellular matrix, the mACs had limited delivery inside the tumor which resulted most of the voxels in the tumor had low fluorescence values [56] [57] [58] . While on the other hand, benefit from the intrinsically leaky nature of tumor vessels compared with healthy vessels in normal organs, which is known as the enhanced permeability and retention (EPR) effect, there was modest delivery for the mACs and the delivered mACs retained mainly near the blood vessels [22] , tumor surface (Fig. 1D ) and in some areas subject to vascular heterogeneity [58, 59] . This may help to explain the appeared another peak on the right end of the histograms in Fig. 2B . We further analyzed the standard deviations (SDs) of the histograms. SD value of tumor of 60 min after PIT showed a significant larger SD than that of before PIT (Fig. 2D) , which indicated the fluorescence values in the histogram transformed toward less variance and may indicate that mACs has a more homogeneous distribution 60 min after PIT. PIT treatment leaded to quick decrease of mACs in the tumor [1] . On one hand, PIT facilitated unbound mAb − IR700 to redistribute into the remnant target tumor. While the areas initially filled with clustered fluorescence signals did not recover to the initial intensity due to the limited recovery time and circulated mACs. This explained the shift to homogeneous distribution of mACs after PIT treatment. We also calculated the number of pixels over the value of LOQ in the tumor before and 60 min after PIT treatment. There were significantly more pixels with values over the threshold in the tumor 60 min after PIT treatment than that of before PIT (Fig. 2E) . PIT selectively destructed the perivascular layers of cancer cells leading to expansion of the tumor vessel diameter and allowing more fully distribution of circulated mACs throughout the treated tumor than before PIT, which can explain the increased pixels over the threshold. On the other hands, we can notice that the volume intensity after PIT treatment did not recover to the initial value ( Fig. 2A) , which may be due to the limited quantity of mAb−IR700 conjugate in the circulation system and limited recovery time. Entropy measures the randomness of the intensities in the image [60] . Entropies of pixel values before and 60 min after PIT treatment were also presented. The pixels in the tumor 60 min after PIT have significant smaller entropy than that of tumor before PIT (Fig. 2F) . The pixels in the tumor before PIT had more contrast with different values due to the heterogeneous distribution of the mACs and significant smaller entropy 60 min after PIT resulting from the more homogeneous distribution of the mACs. One distinct advantage of the FLOT/OCT system is that we can quantitatively monitor the trend of the 3D mACs micro-distribution in vivo and in situ, thus providing a multi-parameters analysis about the change of the tumor microenvironment during and after PIT treatment.
In vivo imaging the distribution of the mACs at different intra-tumor depths using FLOT/OCT system
Since the FLOT/OCT system can provide depth-resolved information of the tumor structure and drug distribution non-invasively, representative cross-sections from the 3D FLOT/OCT tumor images at different time points during and after PIT treatment are shown in Fig. 3A . At 0 min, the scattered mACs in the tumor at different depths can be clearly resolved. The mACs distributed in a heterogeneous manner and some areas filled with clustered fluorescence signals especially in the tumor surface. When the NIR LED irradiation began, the IR700 fluorescence intensity dropped quickly at both tumor surface and deep tumor regions. After 20 min PIT treatment, the IR700 fluorescence intensity recovered as described before. The IR700 fluorescence intensity in the areas with clustered fluorescence signals seems undergoing a quicker recovery. After 60 min, the IR700 fluorescence intensity showed a more homogeneous distribution in the tumor. To indicate the heterogeneity of the recovery in IR700 fluorescence intensity, region of interest (ROI) (50 × 30 × 15 pixels) from tumor surface (dashed blue box as shown in the Fig. 3A at 80 min) and deep tumor (dashed red box as shown in the Fig. 3A at 80 min) were averaged to show the changes in fluorescence during and after PIT. The IR700 fluorescence intensity was further normalized to the corresponding initial level (0 min). The normalized IR700 fluorescence intensity clearly dropped more in the tumor surface at 20 min (Fig. 3B) . The recovery of IR700 fluorescence intensity (at 80 min) in deep tumor was significantly higher than that of the tumor surface (Fig. 3C) . There was not any clear change of the mACs distribution in control tumor Fig. 3A) .
With H&E staining, there is more cell necrosis in tumor surface compared to deep tumor (Fig. 3E) . More mAb-IR700 was found in the deep tumor after PIT treatment (Supplementary Fig. 2D ). In the control tumor, no obvious cell necrosis was observed in either tumor surface or the deep tumor ( Supplementary Fig. 3B ).
With the proposed FLOT/OCT system, we evaluated the 3D microdistribution of mACs at different depths with a very minimally invasive manner (since we need to remove the skin over the tumor). And currently we are working on improving the penetration depth of the system thus we could have the skin intact in the near future [49] . As observed before, tumors surface showed significantly higher IR700 fluorescence intensity value than that of the deep tumor before PIT due to the penetration limitation of the mACs (Fig. 1E) , while the recovery of IR700 fluorescence intensity (at 80 min) in deep tumor was significantly higher than that of the tumor surface (Fig. 3C) . After PIT treatment, the perivascular layers of cancer cells were selectively destructed and the mACs had easier access to the deep tumor's extravascular space compared to before [22] . Although less mACs were needed to recover or outnumber its initial value for deep tumor, the higher recovery of mACs in deep tumor did provide some cues about the SUPR effect [22] .
In vivo imaging the distribution of the mACs and tumor vasculature using FLOT/OCT system
In this study, the tumor vasculature was also obtained using the multi-wavelength FLOT system to further investigate the mACs distribution during and after PIT. The left image of Fig. 4A shows the 3D tumor structure obtained from OCT, with the shape of tumor clearly displayed. The middle image of Fig. 4A shows the 3D vasculature on the same tumor acquired from multi-wavelength FLOT system. The tortuous blood vessels (green) with different sizes are clearly presented. The right image of Fig. 4A fuses the tumor structure with tumor vasculature. The mACs distribution (orange-red) during and after PIT treatment is superimposed with 3D tumor structure and 3D vasculature in Fig. 4B . Before PIT treatment at 0 min, as observed before, the distribution of mACs was heterogeneous with some areas filling with clustered fluorescence signals. The relative distribution of mACs with respect to the blood vessels in different tumor areas could be visualized clearly. After NIR irradiation began, the expected drop of IR700 fluorescence intensity occurred quickly in the entire tumor. From 25 min to 40 min, the IR700 fluorescence intensity in the areas with clustered fluorescence signals began to recover. From 50 min, the mACs started to fill most of the tumor areas in a more homogeneous way. Interestingly the fluorescence distribution achieved a bigger area coverage than that of the initial point (0 min), meaning the drug accessed more tumor areas after NIR-PIT treatment. MACs in the control tumor did not show obvious change (Supplementary Fig. 4B ). Different small regions (5 × 5 × 5 pixels) from various locations of the tumor were picked to show the changes in fluorescence during and after PIT (Fig. 4C) . We intended to label the areas having clustered fluorescence signals initially with small numbers (e.g. 1-5), the areas having weak fluorescence signals initially with big numbers (e.g. 6-10). The areas with small numbers had a quick but less recovery while the recovery for areas with large numbers mainly happened after 40 min and the recovery reached to a higher value than that of the initial status (0 min). There are no significant changes of IR700 fluorescence in different areas in the control mice but some small fluctuations ( Supplementary  Fig. 4C and D) .
In vivo imaging the distribution of the mACs using two-photon microscopy
To verify the results obtained from FLOT/OCT system, we further applied TPM system to investigate the mACs distribution during and after PIT. GFP was also employed as a surrogate of cell death and to make the blood vessels more visible. The nearly intact tumor was placed under the two-photon objective lens for imaging after removing the skin over it. The imaging ROIs were selected to include blood vessels/capillaries. As shown in Fig. 5A , before NIR irradiation, most of the mACs clustered around the blood vessels. Immediately after turning on the NIR LED, the IR700 fluorescence decreased quickly. The GFP signals also decreased while the blood vessels can still be clearly distinguished. After NIR LED irradiation finished, the IR700 fluorescence showed quick recovery surrounding the blood vessels and extended to a bigger region from the blood vessel. In the control mice receiving no NIR irradiation, there were no significant changes of IR700 distribution and GFP fluorescence (Supplementary Fig. 5A ). Similarly, changes in IR700 fluorescence from selected areas showed higher recovery in the areas initially (0 min) with less mACs (Fig. 5B) . The areas with larger distances from the blood vessels (e.g. areas 6 and 7) also achieved higher recovery of IR700 fluorescence after PIT treatment. We can conclude that PIT can promote the delivery of mACs especially into the areas where were initially difficult for mACs to reach (Figs. 4C and 5B), which resulted from enhancement of permeability and retention. There were no significant changes of IR700 fluorescence in different selected areas in the control mice without NIR irradiation ( Supplementary  Fig. 5B and C) .
The histograms of the pixels before and 60 min after PIT in the tumor were plotted in Fig. 5C . Before PIT treatment, there were two peaks at left and right edges of the histogram. And 60 min after PIT treatment, the entire histogram shifted to the middle range while the control group did not have such trend (Supplementary Fig. 5D ). The pixels with values over background in the tumor were also calculated before and 60 min after PIT treatment. There were significantly more pixels with values over background in the tumor 60 min after PIT treatment than that of before PIT (Fig. 5D) . We further analyzed the entropy of pixels in the tumor before and 60 min after PIT treatment. The pixels in the tumor 60 min after PIT have significant smaller entropy than that of tumor before PIT (Fig. 5E) . Moreover, in this study, we also investigated the micro-distribution of mACs in the tumorbearing mice implanted with MDAMB468 cells except A431 cells and they provided very consistent results.
Conclusions
We investigated the 3D micro-distribution of mACs during/after PIT in situ and in vivo using FLOT/OCT imaging and high-resolution twophoton microscopy. The distribution of mACs was improved after PIT treatment with more mACs reaching more areas in the tumor. Being able to quantitatively monitor 3D theranostic agent distribution and therapeutic effects including cellular necrosis within the tumor in vivo and in real time, these novel imaging methods can serve as new platforms for further understanding the PIT/SUPR mechanism as well as other tumor-targeted drug delivery systems, thus optimizing the effectiveness of treatment. Due to the low penetration depth, this new multimodal imaging technology is applicable predominantly for applications in which tissues of interest are superficial, such as the exposed mouse brain, skin, and preclinical research at current stage. While, the two imaging modalities could be integrated into a functional endoscopy system using microelectromechanical system (MEMS), Gradient-index (GRIN) cylindrical lens and imaging fiber bundle in the future for more studies on different disease models and potentially clinical applications [61] .
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